Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients.

ABSTRACT: To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV₁) at the follow-up visit compared to baseline; reduction in corticosteroid dose at

SUBMITTER: Domingo C 

PROVIDER: S-EPMC11989120 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature